http://bmctoday.net/citoday/ The latest news stories from Cardiac Interventions Today. en-us Sun, 19 May 2013 22:31:47 GMT Sun, 19 May 2013 22:31:47 GMT BMCToday http://bmctoday.net/citoday/2013/04/article.asp?f=st-jude-medicals-ilumien-optis-3-d-pci-optimization-system-approved-in-europe May 16, 2013—St. Jude Medical, Inc. (St. Paul, MN) announced CE Mark approval of the Ilumien Optis percutaneous coronary intervention (PCI) optimization system, a comprehensive disease assessment tool for treating patients with coronary artery disease (CAD). The company announced in March that the Ilumien Optis system was... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=st-jude-medicals-ilumien-optis-3-d-pci-optimization-system-approved-in-europe http://bmctoday.net/citoday/2013/04/article.asp?f=trial-commences-for-european-approval-of-circulites-synergy-ic-circulatory-support-system May 15, 2013—CircuLite, Inc. (Teaneck, NJ) announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE Mark trial of the company’s Synergy IC circulatory support system, which is designed for cannula deployment by an interventional cardiologist. Acco... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=trial-commences-for-european-approval-of-circulites-synergy-ic-circulatory-support-system http://bmctoday.net/citoday/2013/04/article.asp?f=st-jude-medical-begins-enlightn-iii-study-for-next-generation-renal-denervation-system May 14, 2013—St. Jude Medical, Inc. (St. Paul, MN) announced the commencement of enrollment in the EnligHTN III trial that will evaluate the safety and performance of the company’s second-generation EnligHTN renal denervation system in patients with drug-resistant, uncontrolled hypertension. According to St. Jude Med... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=st-jude-medical-begins-enlightn-iii-study-for-next-generation-renal-denervation-system http://bmctoday.net/citoday/2013/04/article.asp?f=neovasc-completes-cosira-enrollment May 13, 2013—Neovasc Inc. (Vancouver, BC) announced the completion of patient enrollment in its COSIRA trial, which is designed to further assess the efficacy and safety of the Neovasc Reducer, a percutaneous device for the treatment of refractory angina. The a href="http://www.clinicaltrials.gov/ct2/show/NCT01205893" ... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=neovasc-completes-cosira-enrollment http://bmctoday.net/citoday/2013/04/article.asp?f=poseidon-supports-sliding-scale-hydration-to-prevent-contrast-induced-kidney-complications May 9, 2013—A new method of dynamic, personalized, intravenous hydration significantly reduces the percentage of contrast-induced kidney injury from image-guided cardiovascular procedures, according to the results of the POSEIDON trial presented as a late-breaking clinical trial at the Society for Cardiovascular Angiograp... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=poseidon-supports-sliding-scale-hydration-to-prevent-contrast-induced-kidney-complications http://bmctoday.net/citoday/2013/04/article.asp?f=biosensors-to-acquire-spectrum-dynamics May 13, 2013—Biosensors International Group, Ltd. (Singapore) announced that it has entered into an agreement to acquire the assets of Spectrum Dynamics Ltd. (Caesarea, Israel), a manufacturer of advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions. The annou... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=biosensors-to-acquire-spectrum-dynamics http://bmctoday.net/citoday/2013/04/article.asp?f=review-of-ffr-usage-suggests-borderline-coronary-blockages-may-be-higher-risk-than-assumed May 9, 2013— The Society of Cardiovascular Angiography and Interventions (SCAI) announced a study showing that when stenting or bypass surgical treatment of a coronary blockage is deferred because of a borderline fractional flow reserve (FFR) result, patients are far more likely to eventually need a coronary procedure tha... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=review-of-ffr-usage-suggests-borderline-coronary-blockages-may-be-higher-risk-than-assumed http://bmctoday.net/citoday/2013/04/article.asp?f=protect-af-4-year-data-support-boston-scientifics-watchman-laa-closure-device May 9, 2013—Boston Scientific Corporation (Natick, MA) announced that 4-year follow-up data from the PROTECT AF clinical trial demonstrated that the company’s Watchman left atrial appendage (LAA) closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke, and systemic emb... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=protect-af-4-year-data-support-boston-scientifics-watchman-laa-closure-device http://bmctoday.net/citoday/2013/04/article.asp?f=statistical-analysis-supports-renal-denervation-for-treating-hypertension-across-age-groups May 9, 2013—The Society of Cardiovascular Angiography and Interventions (SCAI) announced the presentation of data suggesting that catheter-based renal denervation is projected to improve blood pressure and substantially reduce the incidence of major cardiovascular events in patients whose high blood pressure has not been ... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=statistical-analysis-supports-renal-denervation-for-treating-hypertension-across-age-groups http://bmctoday.net/citoday/2013/04/article.asp?f=fda-approves-excella-iii-trial-of-elixirs-desyne-nx-stent May 8, 2013—Elixir Medical Corporation (Sunnyvale, CA) announced that it has received approval from the US Food and Drug Administration (FDA) to initiate patient enrollment in the EXCELLA III clinical trial at up to 50 institutions the United States. EXCELLA III will enroll patients with conditions to be addressed in para... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=fda-approves-excella-iii-trial-of-elixirs-desyne-nx-stent http://bmctoday.net/citoday/2013/04/article.asp?f=societies-update-clinical-competency-criteria-for-quality-coronary-interventions May 8, 2013—Criteria for evaluating operator competency for performing coronary interventions should be expanded beyond procedure volume and include an evaluation of risk-adjusted outcomes, periodic case reviews of patient selection, and other factors, according to a new report from the American College of Cardiology (ACC... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=societies-update-clinical-competency-criteria-for-quality-coronary-interventions http://bmctoday.net/citoday/2013/04/article.asp?f=atrium-medical-announces-1-year-results-of-the-infuse-ami-trial May 3, 2013—Atrium Medical Corporation (Hudson, NH), a business unit of Maquet Cardiovascular (Wayne, NJ), announced the 1-year results of the a href="http://www.clinicaltrials.gov/ct2/show/NCT00976521" class="" classname="" target="" name=""INFUSE-AMI/a (Abciximab and Aspiration Thrombectomy in Patients With Large Anteri... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/citoday/2013/04/article.asp?f=atrium-medical-announces-1-year-results-of-the-infuse-ami-trial